Trade

with

XenoPort Inc
(NASDAQ: XNPT)
AdChoices
6.30
-0.05
-0.79%
After Hours :
6.30
0.00
0.00%

Open

6.39

Previous Close

6.35

Volume (Avg)

374.25k (343.88k)

Day's Range

6.27-6.45

52Wk Range

3.15-7.20

Market Cap.

391.93M

Dividend Rate ( Yield )

-

Beta

0.81

Shares Outstanding

62.21M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 7.95M

    • Net Income

    • -85.88M

    • Market Cap.

    • 391.93M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -551.82

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.81

    • Forward P/E

    • -8.87

    • Price/Sales

    • 23.92

    • Price/Book Value

    • 4.09

    • Price/Cash flow

    • -7.69

      • EBITDA

      • -84.22M

      • Return on Capital %

      • -59.58

      • Return on Equity %

      • -85.23

      • Return on Assets %

      • -59.58

      • Book Value/Share

      • 1.54

      • Shares Outstanding

      • 62.21M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 6.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.72

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 155.70

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -28.31

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 86.18

            • 82.75

            • Pre-Tax Margin

            • -551.82

            • 39.38

            • Net Profit Margin

            • -551.82

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 97.10

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -871.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -871.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 3.72

              • 2.92

              • Quick Ratio

              • 3.58

              • 2.35

              • Interest Coverage

              • -172.09

              • 38.02

              • Leverage Ratio

              • 1.52

              • 2.21

              • Book Value/Share

              • 1.54

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.37

                • 277.78

                • P/E Ratio 5-Year High

                • -14.43

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.16

                • 124.82

                • Price/Sales Ratio

                • 24.10

                • 9.35

                • Price/Book Value

                • 4.12

                • 8.50

                • Price/Cash Flow Ratio

                • -7.69

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -85.23

                    (-58.10)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -59.58

                    (-44.80)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -84.74

                    (-58.00)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 1.80

                  • 1.48

                  • Asset Turnover

                  • 0.11

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -85.63M
                  Operating Margin
                  -1,076.95
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -7.69
                  Ownership

                  Institutional Ownership

                  89.55%

                  Top 10 Institutions

                  65.59%

                  Mutual Fund Ownership

                  33.82%

                  Float

                  86.60%

                  5% / Insider Ownership

                  1.87%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • VA CollegeAmerica Small Cap World

                  •  

                    4,769,000

                  • 0.00

                  • 7.67

                  • JPM Global Healthcare

                  •  

                    2,583,221

                  • 0.00

                  • 4.15

                  • Vanguard Total Stock Mkt Idx

                  •  

                    910,528

                  • 0.00

                  • 1.46

                  • iShares Russell 2000 (AU)

                  •  

                    899,056

                  • -0.89

                  • 1.71

                  • iShares Nasdaq Biotechnology

                  •  

                    810,551

                  • -1.85

                  • 1.54

                  • Fidelity Advisor® Capital Development

                  •  

                    791,908

                  • 0.00

                  • 1.27

                  • Fidelity Advisor® Diversified Stock Fund

                  •  

                    650,000

                  • 0.00

                  • 1.04

                  • Fidelity® Large Cap Stock Fund

                  •  

                    623,517

                  • 0.00

                  • 1.00

                  • Wellington Global Health Care Eq Port

                  •  

                    566,390

                  • -8.81

                  • 0.91

                  • Vanguard Extended Market Index Fund

                  •  

                    515,854

                  • 3.52

                  • 0.83

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Wellington Management Company, LLP

                  •  

                    8,592,106

                  • +3.15%

                  • 13.84

                  • Orbimed Advisors, LLC

                  •  

                    5,546,100

                  • 0.00%

                  • 8.93

                  • Capital World Investors

                  •  

                    4,769,000

                  • 0.00%

                  • 7.68

                  • Deerfield Management Co

                  •  

                    4,427,642

                  • +0.98%

                  • 7.13

                  • J P Morgan Asset Management (UK) Ltd

                  •  

                    2,583,619

                  • -17.36%

                  • 4.16

                  • Fidelity Management and Research Company

                  •  

                    2,579,267

                  • +3.89%

                  • 4.15

                  • BlackRock Fund Advisors

                  •  

                    2,175,394

                  • -4.06%

                  • 3.50

                  • Vanguard Group, Inc.

                  •  

                    1,641,574

                  • +3.19%

                  • 2.64

                  • Millennium Management LLC

                  •  

                    1,611,438

                  • -36.37%

                  • 2.60

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  XenoPort, Inc., is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potentia...morel treatment of neurological disorders. Its product candidates are prodrugs that are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and metabolism of the parent drug. Its marketed product and each of its product candidates are orally available, patented molecules that address potential markets with clear unmet medical needs. Its marketed product is approved in the United States, where it is known as Horizant Extended-Release Tablets, and in J...moreapan, where it is known as Regnite Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with moderate-to-severe RLS. It is also engaged with third parties for the development of arbaclofen placarbil, or AP, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease. With respect to AP, it has decided to terminate further investment in AP as a treatment for spasticity in patients with MS; however, given a previous, successful Phase 2 clinical trial of AP as a potential treatment for spasticity in spinal cord injury patients. XP21279, in the primary analysis of the trial, the improvement with XP21279/carbidopa dosed three times per day was not statistically good than the improvement seen with optimized Sinemet dosed four or five times per day during the double-blind phase of the trial. It has discussed the results of this trial with experts in Parkinson’s disease and with regulatory authorities. As a result, it plans to continue development of XP21279 to the extent its resources permit or it enters into collaboration with a third party. The Company faces competition from manufacturers of generic drugs. The Company is subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as governmental authorities in those foreign countries in which it may commercialize its products.lessless

                  Key People

                  Dr. Ronald W. Barrett,PhD

                  CEO/Director/Founder

                  William G. Harris

                  CFO/Chief Accounting Officer/Senior VP, Divisional

                  Vincent J. Angotti

                  Executive VP/COO

                  Jeryl L. Hilleman

                  Director

                  Dr. Wendell D. Wierenga,PhD

                  Director

                  • XenoPort Inc

                  • 3410 Central Expressway

                  • Santa Clara, CA 95051

                  • USA.Map

                  • Phone: +1 408 616-7200

                  • Fax: -

                  • xenoport.com

                  Incorporated

                  1999

                  Employees

                  92

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: